Skip to content

A new key to block hepatitis B transcription: exploring the potential of NAAA enzyme

Study on the role and mechanism of N-acetylethanolamine amidase NAAA in inhibiting HBV transcription

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111028
Enrollment
Unknown
Registered
2025-10-23
Start date
2025-10-25
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

Patients with positive HBsAg:None
Healthy control group:None

Sponsors

The Affiliated Hospital of Guilin Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Inclusion criteria for the Chronic hepatitis B group: (1) aged 18-65 years, regardless of gender; (2) diagnosed with chronic hepatitis B according to the Guidelines for the Prevention and Treatment of Chronic Hepatitis B; (3) no history of other viral hepatitis (e.g., HCV or HDV) or liver cirrhosis/cancer; (4) voluntary signing of the informed consent form. 2.Inclusion criteria for the control group: (1) aged 18-65 years, regardless of gender; (2) patients definitively ruled out for chronic hepatitis B diagnosis according to the Guidelines for the Prevention and Treatment of Chronic Hepatitis B (e.g., HBsAg negative, undetectable HBV DNA, normal liver function and no evidence of hepatitis activity); (3) no history of other viral hepatitis (e.g., HCV or HDV) or liver cirrhosis/cancer; (4) voluntary signing of the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Exclusion criteria for the Chronic hepatitis B group: (1) received antiviral therapy or immunomodulatory therapy within the past 6 months; (2) presence of severe comorbidities (e.g., uncontrolled heart failure, renal failure, autoimmune diseases); (3) poor compliance (e.g., inability to complete follow-up or refusal to sign informed consent). 2.Exclusion criteria for the healthy control group: (1) presence of other viral hepatitis (e.g., HCV or HDV) or HIV infection; (2) comorbid metabolic diseases (e.g., diabetes, fatty liver disease) or severe cardiac or renal dysfunction; (3) pregnancy or lactation in female subjects.

Design outcomes

Primary

MeasureTime frame
Gene expression status: NAAA, MMS19, XPD, XPB, etc.;

Secondary

MeasureTime frame
Serum PEA content;

Countries

China

Contacts

Public ContactYong Zhang

The Affiliated Hospital of Guilin Medical College

zhangyong@glmc.edu.cn+86 773 2833023

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026